美国退伍军人健康管理局直接抗病毒药物时代丙型肝炎病毒照护连续体的成功
研究描述了美国退伍军人健康管理局2014年1月1日至2022年12月31日丙型肝炎照护连续体,纳入2021-2022年在管且符合直接抗病毒治疗条件的退伍军人。133,732例丙肝病毒血症退伍军人中,107,134例(80.1%)启动治疗,98,136例(91.6%)获得持续病毒学应答;获得应答者中1,097例(1.1%)再次出现病毒血症,579例(52.8%)再次治疗。年轻、不稳定住房及兴奋剂使用与照护连续体各环节负相关。
要点
- 133,732例丙肝病毒血症退伍军人中80.1%启动直接抗病毒治疗。
- 治疗者中91.6%获得持续病毒学应答,再病毒血症仅1.1%。
- 年轻、不稳定住房及兴奋剂使用与照护连续体各环节负相关。
核心结论
- 退伍军人健康管理局已治疗2021-2022年在管丙肝退伍军人的80%,治疗者中超过90%获得持续病毒学应答。
- 再病毒血症罕见,与年轻年龄、不稳定住房、阿片类药物使用及兴奋剂使用相关。
- 需要持续努力覆盖年轻退伍军人以及有不稳定住房或物质使用障碍的退伍军人。
研究设计与样本
- 研究纳入2021-2022年在退伍军人健康管理局在管且2014年1月1日至2022年12月31日符合直接抗病毒治疗条件的个体。
- 评估各照护连续体环节进展比例,并识别与启动直接抗病毒药物、获得持续病毒学应答及再病毒血症相关的因素。
主要发现
- 识别133,732例丙肝病毒血症退伍军人,107,134例(80.1%)启动丙肝治疗。
- 98,136例(91.6%)获得持续病毒学应答。
- 获得持续病毒学应答者中1,097例(1.1%)再次出现病毒血症,其中579例(52.8%)再次接受丙肝治疗。
- 较年轻退伍军人启动治疗和获得持续病毒学应答的可能性较低,再病毒血症的可能性较高。
- 兴奋剂使用和不稳定住房与丙肝照护连续体各环节呈负相关。
临床怎么用
- 退伍军人健康管理局已治疗2021-2022年在管丙肝退伍军人的80%,治疗者中超过90%获得持续病毒学应答。
- 再病毒血症罕见,与年轻年龄、不稳定住房、阿片类药物使用及兴奋剂使用相关。
- 需要持续努力覆盖年轻退伍军人以及有不稳定住房或物质使用障碍的退伍军人。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estimated hepatitis C prevalence within the Veterans Health Administration is higher than the general population and is a risk factor for advanced liver disease and subsequent complications. We describe the hepatitis C care continuum within the Veterans Health Administration 1 January 2014 to 31 December 2022. METHODS: We included individuals in Veterans Health Administration care 2021-2022 who were eligible for direct-acting antiviral treatment 1 January 2014 to 31 December 2022. We evaluated the proportion of Veterans who progressed through each step of the hepatitis C care continuum, and identified factors associated with initiating direct-acting antivirals, achieving sustained virologic response, and repeat hepatitis C viremia. RESULTS: We identified 133 732 Veterans with hepatitis C viremia. Hepatitis C treatment was initiated in 107 134 (80.1%), with sustained virologic response achieved in 98 136 (91.6%). In those who achieved sustained virologic response, 1097 (1.1%) had repeat viremia and 579 (52.8%) were retreated for hepatitis C. Veterans of younger ages were less likely to initiate treatment and achieve sustained virologic response, and more likely to have repeat viremia. Stimulant use and unstable housing were negatively associated with each step of the hepatitis C care continuum. CONCLUSIONS: The Veterans Health Administration has treated 80% of Veterans with hepatitis C in care 2021-2022 and achieved sustained virologic response in more than 90% of those treated. Repeat viremia is rare and is associated with younger age, unstable housing, opioid use, and stimulant use. Ongoing efforts are needed to reach younger Veterans, and Veterans with unstable housing or substance use disorders.
引用
- Varley CD, Lowy E, Cartwright EJ, et al. Success of the US Veterans Health Administration's Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era. Clin Infect Dis. 2024. PMID: 38279939. doi:10.1093/cid/ciae025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。